Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.54 |
| ▸ | CCR2 | P41597 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 8/20 | 0.48 |
| ▸ | JAK2 | O60674 | 7/20 | 0.48 |
| ▸ | TYK2 | P29597 | 6/20 | 0.48 |
| ▸ | JAK3 | P52333 | 6/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4785854 | 1.00 | ROCK1 (0.54) | ROCK1ROCK2CCR2KCNH2JAK1 | |
| Hydrochloric Acid SCHEMBL952987 | 0.77 | ROCK1 (0.55) | ROCK1ROCK2CCR2KCNH2 | |
| SCHEMBL7463143 | 0.77 | ROCK1 (0.50) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL10608943 | 0.77 | ROCK1 (0.66) | ROCK1ROCK2CCR2KCNH2MCHR1 | |
| SCHEMBL5639778 | 0.76 | ROCK1 (0.88) | ROCK1ROCK2CCR2KCNH2 | |
| SCHEMBL5637873 | 0.76 | ROCK1 (0.88) | ROCK1ROCK2CCR2KCNH2 | |
| SCHEMBL5637871 | 0.76 | ROCK1 (0.88) | ROCK1ROCK2CCR2KCNH2 | |
| SCHEMBL10607825 | 0.76 | HRH3 (0.62) | ROCK1ROCK2CCR2MCHR1CHEK2 | |
| SCHEMBL10970487 | 0.74 | MCHR1 (0.58) | ROCK1ROCK2CCR2MCHR1 | |
| SCHEMBL7468234 | 0.74 | ROCK1 (0.54) | ROCK1ROCK2CCR2KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| WO-2008079909-A1 | PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079909-A1 | PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ROCK1 369/4885ROCK2 374/4885CCR2 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.